A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis

Peter C. Taylor*, Desiree van der Heijde, Robert Landewe, Shannon McCue, Sue Cheng, Annelies Boonen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1259-1267
Number of pages9
JournalJournal of Rheumatology
Volume48
Issue number8
DOIs
Publication statusPublished - 1 Aug 2021

Keywords

  • ankylosing spondylitis
  • apremilast
  • autoimmune diseases
  • biologic therapy
  • clinical trials
  • SEVERE PLAQUE PSORIASIS
  • CONTROLLED-TRIAL
  • EFFICACY
  • SAFETY
  • RECOMMENDATIONS
  • ARTHRITIS
  • MODERATE

Cite this